221 related articles for article (PubMed ID: 31419298)
1. WHO grade has no prognostic value in the pediatric high-grade glioma included in the HERBY trial.
Varlet P; Le Teuff G; Le Deley MC; Giangaspero F; Haberler C; Jacques TS; Figarella-Branger D; Pietsch T; Andreiuolo F; Deroulers C; Jaspan T; Jones C; Grill J
Neuro Oncol; 2020 Jan; 22(1):116-127. PubMed ID: 31419298
[TBL] [Abstract][Full Text] [Related]
2. Radiological Evaluation of Newly Diagnosed Non-Brainstem Pediatric High-Grade Glioma in the HERBY Phase II Trial.
Rodriguez Gutierrez D; Jones C; Varlet P; Mackay A; Warren D; Warmuth-Metz M; Aliaga ES; Calmon R; Hargrave DR; Cañete A; Massimino M; Azizi AA; Le Deley MC; Saran F; Rousseau RF; Zahlmann G; Garcia J; Vassal G; Grill J; Morgan PS; Jaspan T
Clin Cancer Res; 2020 Apr; 26(8):1856-1865. PubMed ID: 31924736
[TBL] [Abstract][Full Text] [Related]
3. Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial.
Mackay A; Burford A; Molinari V; Jones DTW; Izquierdo E; Brouwer-Visser J; Giangaspero F; Haberler C; Pietsch T; Jacques TS; Figarella-Branger D; Rodriguez D; Morgan PS; Raman P; Waanders AJ; Resnick AC; Massimino M; Garrè ML; Smith H; Capper D; Pfister SM; Würdinger T; Tam R; Garcia J; Thakur MD; Vassal G; Grill J; Jaspan T; Varlet P; Jones C
Cancer Cell; 2018 May; 33(5):829-842.e5. PubMed ID: 29763623
[TBL] [Abstract][Full Text] [Related]
4. Phase II, Open-Label, Randomized, Multicenter Trial (HERBY) of Bevacizumab in Pediatric Patients With Newly Diagnosed High-Grade Glioma.
Grill J; Massimino M; Bouffet E; Azizi AA; McCowage G; Cañete A; Saran F; Le Deley MC; Varlet P; Morgan PS; Jaspan T; Jones C; Giangaspero F; Smith H; Garcia J; Elze MC; Rousseau RF; Abrey L; Hargrave D; Vassal G
J Clin Oncol; 2018 Apr; 36(10):951-958. PubMed ID: 29412784
[TBL] [Abstract][Full Text] [Related]
5. Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location.
Karremann M; Gielen GH; Hoffmann M; Wiese M; Colditz N; Warmuth-Metz M; Bison B; Claviez A; van Vuurden DG; von Bueren AO; Gessi M; Kühnle I; Hans VH; Benesch M; Sturm D; Kortmann RD; Waha A; Pietsch T; Kramm CM
Neuro Oncol; 2018 Jan; 20(1):123-131. PubMed ID: 29016894
[TBL] [Abstract][Full Text] [Related]
6. The prognostic value of clinical factors and cancer stem cell-related markers in gliomas.
Dahlrot RH
Dan Med J; 2014 Oct; 61(10):B4944. PubMed ID: 25283629
[TBL] [Abstract][Full Text] [Related]
7. Impact of tumor location and pathological discordance on survival of children with midline high-grade gliomas treated on Children's Cancer Group high-grade glioma study CCG-945.
Eisenstat DD; Pollack IF; Demers A; Sapp MV; Lambert P; Weisfeld-Adams JD; Burger PC; Gilles F; Davis RL; Packer R; Boyett JM; Finlay JL
J Neurooncol; 2015 Feb; 121(3):573-81. PubMed ID: 25431150
[TBL] [Abstract][Full Text] [Related]
8. Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas.
Schreck KC; Ranjan S; Skorupan N; Bettegowda C; Eberhart CG; Ames HM; Holdhoff M
J Neurooncol; 2019 May; 143(1):87-93. PubMed ID: 30864101
[TBL] [Abstract][Full Text] [Related]
9. Antiangiogenic therapy for high-grade glioma.
Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
[TBL] [Abstract][Full Text] [Related]
10. A pilot study of bevacizumab-based therapy in patients with newly diagnosed high-grade gliomas and diffuse intrinsic pontine gliomas.
Hummel TR; Salloum R; Drissi R; Kumar S; Sobo M; Goldman S; Pai A; Leach J; Lane A; Pruitt D; Sutton M; Chow LM; Grimme L; Doughman R; Backus L; Miles L; Stevenson C; Fouladi M; DeWire M
J Neurooncol; 2016 Mar; 127(1):53-61. PubMed ID: 26626490
[TBL] [Abstract][Full Text] [Related]
11. Children with DIPG and high-grade glioma treated with temozolomide, irinotecan, and bevacizumab: the Seattle Children's Hospital experience.
Crotty EE; Leary SES; Geyer JR; Olson JM; Millard NE; Sato AA; Ermoian RP; Cole BL; Lockwood CM; Paulson VA; Browd SR; Ellenbogen RG; Hauptman JS; Lee A; Ojemann JG; Vitanza NA
J Neurooncol; 2020 Jul; 148(3):607-617. PubMed ID: 32556862
[TBL] [Abstract][Full Text] [Related]
12. Anti-angiogenic therapy for high-grade glioma.
Ameratunga M; Pavlakis N; Wheeler H; Grant R; Simes J; Khasraw M
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD008218. PubMed ID: 30480778
[TBL] [Abstract][Full Text] [Related]
13. Characterizing and targeting PDGFRA alterations in pediatric high-grade glioma.
Koschmann C; Zamler D; MacKay A; Robinson D; Wu YM; Doherty R; Marini B; Tran D; Garton H; Muraszko K; Robertson P; Leonard M; Zhao L; Bixby D; Peterson L; Camelo-Piragua S; Jones C; Mody R; Lowenstein PR; Castro MG
Oncotarget; 2016 Oct; 7(40):65696-65706. PubMed ID: 27582545
[TBL] [Abstract][Full Text] [Related]
14. Concurrent radiotherapy with temozolomide vs. concurrent radiotherapy with a cisplatinum-based polychemotherapy regimen : Acute toxicity in pediatric high-grade glioma patients.
Seidel C; von Bueren AO; Bojko S; Hoffmann M; Pietsch T; Gielen GH; Warmuth-Metz M; Bison B; Kortmann RD; Kramm CM
Strahlenther Onkol; 2018 Mar; 194(3):215-224. PubMed ID: 29022050
[TBL] [Abstract][Full Text] [Related]
15. Pseudoprogression in children, adolescents and young adults with non-brainstem high grade glioma and diffuse intrinsic pontine glioma.
Carceller F; Fowkes LA; Khabra K; Moreno L; Saran F; Burford A; Mackay A; Jones DT; Hovestadt V; Marshall LV; Vaidya S; Mandeville H; Jerome N; Bridges LR; Laxton R; Al-Sarraj S; Pfister SM; Leach MO; Pearson AD; Jones C; Koh DM; Zacharoulis S
J Neurooncol; 2016 Aug; 129(1):109-21. PubMed ID: 27180091
[TBL] [Abstract][Full Text] [Related]
16. High frequency of H3 K27M mutations in adult midline gliomas.
Ebrahimi A; Skardelly M; Schuhmann MU; Ebinger M; Reuss D; Neumann M; Tabatabai G; Kohlhof-Meinecke P; Schittenhelm J
J Cancer Res Clin Oncol; 2019 Apr; 145(4):839-850. PubMed ID: 30610375
[TBL] [Abstract][Full Text] [Related]
17. Radiotherapy versus radiotherapy combined with temozolomide in high-risk low-grade gliomas after surgery: study protocol for a randomized controlled clinical trial.
Wang J; Wang Y; He Y; Guan H; He L; Mu X; Peng X
Trials; 2019 Nov; 20(1):641. PubMed ID: 31752981
[TBL] [Abstract][Full Text] [Related]
18. Treatment of high-grade glioma in children and adolescents.
MacDonald TJ; Aguilera D; Kramm CM
Neuro Oncol; 2011 Oct; 13(10):1049-58. PubMed ID: 21784756
[TBL] [Abstract][Full Text] [Related]
19. Pulvinar Locus is Highly Relevant to Patients' Outcomes in Surgically Resected Thalamic Gliomas in Children.
Chiba K; Aihara Y; Masui K; Abe K; Komori T; Kawamata T
World Neurosurg; 2020 Feb; 134():e530-e539. PubMed ID: 31704359
[TBL] [Abstract][Full Text] [Related]
20. Prognostic impact of distinct genetic entities in pediatric diffuse glioma WHO-grade II-Report from the German/Swiss SIOP-LGG 2004 cohort.
Falkenstein F; Gessi M; Kandels D; Ng HK; Schmidt R; Warmuth-Metz M; Bison B; Krauss J; Kortmann RD; Timmermann B; Thomale UW; Albert MH; Pekrun A; Maaß E; Gnekow AK; Pietsch T
Int J Cancer; 2020 Oct; 147(8):2159-2175. PubMed ID: 32239677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
